Mostrar el registro sencillo del ítem

dc.contributor.authorSanchez-Rovira, P.
dc.contributor.authorZamora, P.
dc.contributor.authorSalvador-Bofill, J.
dc.contributor.authorMorales, S.
dc.contributor.authorMartinez-Janez, N.
dc.contributor.authorMartinez-de-Duenas, E.
dc.contributor.authorLluch, A.
dc.contributor.authorIllarramendi, J. J.
dc.contributor.authorGomez-Pardo, P.
dc.contributor.authorGavila Gregori, J.
dc.contributor.authorGarcia-Palomo, A.
dc.contributor.authorGarcía Mata, Jesús 
dc.contributor.authorFernandez, Y.
dc.contributor.authorDel Barco, S.
dc.contributor.authorde Juan, A.
dc.contributor.authorCiruelos, E.
dc.contributor.authorChacon, J. I.
dc.contributor.authorCalvo, L.
dc.contributor.authorBarnadas, A.
dc.contributor.authorAlbanell, J.
dc.date.accessioned2022-01-27T10:40:50Z
dc.date.available2022-01-27T10:40:50Z
dc.date.issued2019
dc.identifier.issn2155-6660
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493326/pdf/ijda-8-1604375.pdfes
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15968
dc.description.abstractObjective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic treatment of metastatic breast cancer (MBC) according to patient profiles. Methods: A self-administered questionnaire was developed, divided into five sections comprising 34 specific questions related to sequential treatments, plus three additional general questions. Respondents were asked to justify negative answers. Participants were recruited randomly by invitation out of a total of 619 oncologists. The questionnaire was sent and collected via e-mail between October 2015 and May 2016. A total of 191 completed questionnaires were received. Results: Overall, 70% of oncologists would keep the three patient profiles exactly as proposed (hormone receptor-positive and HER2-negative, HER2-positive, and triple negative breast cancer). Affirmative answers to questions regarding treatment sequences for these patient profiles (1-34) ranged from 77.8-99.5%, with an average of 90.9% of oncologists being in agreement with the recommended sequential treatments. The lowest degree of consensus was observed for endocrine treatments in pre-menopausal women and for chemotherapy options in hormone-resistant patients, whilst the highest degree of consensus was reached for targeted therapies in HER2-positive patients and for endocrine therapy in post-menopausal women. In their comments, participants revealed a number of economic constraints that prevented them from implementing some of the best treatment options. Conclusions: In conclusion, despite the complexity of MBC treatment, there is general agreement on the optimal treatment sequences.en
dc.language.isoenges
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.titleBroad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologistsen
dc.typeArtigoes
dc.identifier.doi10.1080/21556660.2019.1604375
dc.identifier.pmid31069129
dc.identifier.sophos32739
dc.issue.number1es
dc.journal.titleJ Drug Assesses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourensees
dc.page.initial62es
dc.page.final69es
dc.rights.accessRightsopenAccesses
dc.subject.keywordCHUOes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number8es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 4.0 Internacional